Back
AbbVie Inc (ABBV)
BiotechnologyABBV · NEW YORK STOCK EXCHANGE, INC. · USD
New to investing? How to read this page →$276.40
+1.45%Weekly undervalued picks (like ABBV)
Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for research and education only. Not financial advice.
Key metrics
EPS
$2.38
ROE
Gross margin
72.0%
Debt/Equity
Revenue growth
12.4%
P/B ratio
Beta
Forward P/E
AbbVie Inc — company intelligence
Earnings surprises
Q2 2026$3.65 vs $3.68 est-0.7%
Q1 2026$2.65 vs $2.65 est+0.2%
Q4 2025$2.71 vs $2.71 est+0.2%
Q3 2025$1.86 vs $1.81 est+2.7%
Analyst consensus · 39 analysts
32 Buy7 Hold0 Sell
Updated Oct 8, 2026
Insider activity · 90 days
0 buys0 sellsnet +0 shares
Donoghoe Nicholasother 32,710 · Aug 14, 2026
Recent SEC filings
8-K — Material event reportOct 5, 2026
4 — Insider transaction reportOct 2, 2026
4 — Insider transaction reportOct 2, 2026
Latest news
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade — Yahoo · 2w ago
ADARx Pharmaceuticals raises $446 million in upsized IPO — Yahoo · 2w ago
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting — Yahoo · 2w ago
AbbVie Stays Flat as 6,000-Property AI Hunts Better Molecules — Yahoo · 2w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
Weekly undervalued picks (like ABBV)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.